SCHEMBL1807571

SCHEMBL1807571

C=C(c1ccc(N(C)C)cc1)c1nc2ccccc2s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.62
NPC1 O15118 8/20 0.62
MAPT P10636 6/20 0.62
ALDH1A1 P00352 3/20 0.62
GAA P10253 1/20 0.62
MCL1 Q07820 1/20 0.62
MEN1 O00255 7/20 0.59
KMT2A Q03164 7/20 0.59
SMN1; SMN2 Q16637 5/20 0.59
LMNA P02545 4/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
APP P05067 2/20 0.55
INSR P06213 2/20 0.50
NCOA1 Q15788 1/20 0.50
THRB P10828 1/20 0.48
RECQL P46063 1/20 0.48
HTT P42858 1/20 0.44
HPGD P15428 1/20 0.43
TSHR P16473 2/20 0.43
CRHBP P24387 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12545717 0.83 RAB9A (0.55) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL2119633 0.81 NPC1 (0.52) RAB9ANPC1MAPTALDH1A1GAA
SCHEMBL2118960 0.75 MMP13 (0.58) RAB9ANPC1MAPTALDH1A1GAA
SCHEMBL12545749 0.73 RECQL (0.65) RAB9ANPC1MAPTALDH1A1GAA
SCHEMBL25761482 0.72 ALOX15 (0.56) RAB9ANPC1MAPTALDH1A1GAA
SCHEMBL11513868 0.71 RAB9A (0.52) RAB9ANPC1MAPTALDH1A1GAA
SCHEMBL13490138 0.71 RAB9A (0.57) RAB9ANPC1MAPTALDH1A1GAA
SCHEMBL27983251 0.71 MEN1 (0.70) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL61917 0.71 APP (1.00) RAB9ANPC1MAPTALDH1A1GAA
SCHEMBL11316978 0.71 CNR2 (0.69) RAB9ANPC1MAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9833458-B2 Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-12-05 US disclosed
US-20150190400-A1 THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2015-07-09 US disclosed
EP-2264018-B1 Thioflavin derivatives for use in the diagnosis of Alzheimer's disease UNIV PITTSBURGH (US) 2015-02-11 EP disclosed
EP-1334091-B1 THIOFLAVIN DERIVATIVES AND THEIR USE IN DIAGNOSIS AND THERAPY OF ALZHEIMER'S DISEASE UNIV PITTSBURGH (US) 2012-09-19 EP disclosed
US-20120095235-A1 THIOFLAVIN DERIVATES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION UNIVERSITY OF PITTSBURGH -- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2012-04-19 US disclosed
US-20110124888-A1 STYRYLBENZOFURAN DERIVATIVES AS INHIBITORS FOR BETA-AMYLOID FIBRIL FORMATION AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2011-05-26 US disclosed
CN-102056910-A Styrylbenzofuran derivatives as inhibitors of beta-amyloid fibril formation and process for preparing the same KOREA INST SCI & TECH 2011-05-11 CN disclosed
EP-2264018-A2 Thioflavin derivatives for use in the diagnosis of Alzheimer's disease University of Pittsburgh of the Commonwealth System of Higher Education (US) 2010-12-22 EP disclosed
US-20080154042-A1 THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMERS DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION UNIVERSITY OF PITTSBURGH 2008-06-26 US disclosed
US-7351401-B2 Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition UNIVERSITY OF PITTSBURGH (US) 2008-04-01 US disclosed
CN-1285582-C Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease UNIV PITTSBURGH (US) 2006-11-22 CN disclosed
US-20050043377-A1 Thioflavin derivatives for use in the antemortem diagnosis of alzheimers disease and in vivo imaging and prevention of amyloid deposition UNIVERSITY OF PITTSBURGH 2005-02-24 US disclosed
CN-1535268-A Thioflavin derivatives for antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposits ƥ�ȱ���ѧ 2004-10-06 CN disclosed
EP-1334091-A2 THIOFLAVIN DERIVATIVES AND THEIR USE IN DIAGNOSIS AND THERAPY OF ALZHEIMER'S DISEASE UNIVERSITY OF PITTSBURGH (US) 2003-08-13 EP disclosed
US-20020133019-A1 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and vivo imaging and prevention of amyloid deposition PITTSBURGH, UNIVERSITY OF 2002-09-19 US disclosed
WO-2002016333-A2 THIOFLAVIN DERIVATIVES AND THEIR USE IN DIAGNOSIS AND THERAPHY OF ALZHEIMER'S DISEASE UNIVERSITY OF PITTSBURGH (US) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095235-A1 THIOFLAVIN DERIVATES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION APP, MAPT, PSEN2 RAB9A 3341/4885NPC1 274/4885MAPT 2/4885
US-20080154042-A1 THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMERS DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION APP, PSEN2, MAPT RAB9A 3337/4885NPC1 300/4885MAPT 3/4885
US-20110124888-A1 STYRYLBENZOFURAN DERIVATIVES AS INHIBITORS FOR BETA-AMYLOID FIBRIL FORMATION AND PREPARATION METHOD THEREOF APP, BACE1, PSEN1 RAB9A 3520/4885NPC1 1142/4885MAPT 7/4885
US-20150190400-A1 THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION APP, PSEN2, MAPT RAB9A 3384/4885NPC1 273/4885MAPT 3/4885
US-20020133019-A1 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and vivo imaging and prevention of amyloid deposition APP, PSEN2, MAPT RAB9A 3392/4885NPC1 279/4885MAPT 3/4885
US-20050043377-A1 Thioflavin derivatives for use in the antemortem diagnosis of alzheimers disease and in vivo imaging and prevention of amyloid deposition APP, PSEN2, MAPT RAB9A 3337/4885NPC1 300/4885MAPT 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.